Development of potent μ-opioid receptor ligands using unique tyrosine analogues of endomorphin-2

Journal of Medicinal Chemistry

Volumn 48, Issue 2, 2005, Pages 586-592

  Li, Tingyou ^a   Fujita, Yoshio ^a   Tsuda, Yuko ^a   Miyazaki, Anna ^a   Ambo, Akihiro ^b   Sasaki, Yusuke ^b   Jinsmaa, Yunden ^c   Bryant, Sharon D ^c   Lazarus, Lawrence H ^c   Okada, Yoshio ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOMORPHIN 2; ENDOMORPHIN 2[1 (2' ETHYL 6' METHYLTYROSINE)]; ENDOMORPHIN 2[1 (2' ISOPROPYL 6' METHYLTYROSINE)]; ENDOMORPHIN 2[1 (2' MONOMETHYLTYROSINE)]; ENDOMORPHIN 2[1 (2',3',6' TRIMETHYLTYROSINE)]; ENDOMORPHIN 2[1 (2',6' DIETHYLTYROSINE)]; ENDOMORPHIN 2[1 (2',6' DIISOPROPYLTYROSINE)]; ENDOMORPHIN 2[1 (2',6' DIMETHYLTYROSINE)]; MU OPIATE RECEPTOR; TYRAMINE; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; CIS TRANS ISOMERISM; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MOUSE; NONHUMAN;

ANALGESICS, OPIOID; ANIMALS; BINDING, COMPETITIVE; BRAIN; GUINEA PIGS; ILEUM; LIGANDS; MALE; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; VAS DEFERENS;

EID: 19944433385     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049384k     Document Type: Article

References (52)

1. 4, (R,R)-(-)1,2-bis[(O-methoxyphenyl)(phenyl) phosphino]ethane(1,5-cyclooctadiene)-rhodium(I) tetrafluoroborate; RP-HPLC, reverse-phase high performance liquid chromatography; TFA, trifluoroacetic acid; TLC, thin-layer chromatography.
2. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Forthergill, L. A.; Morga, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975, 258, 577-579.
3. (a) Ling, N.; Guillemin, R. Morphinomimetics activity of synthetic fragments of β-lipotropin and analogues. Proc. Natl. Acad. Sci. U.S.A. 1976, 7, 3308-3310.
4. (b) Cox, B. M.; Goldstein, A.; Li, C. H. Opioid activity of a peptide β-lipotropin-(61-91), derived form β-lipotropin. Proc. Natl. Acad. Sci. U.S.A. 1976, 73, 1821-1823.
5. Goldstein, A.; Fischli, W.; Lowney, L. I.; Hunkapilier, M.; Hood, L. Porcine pituitary dynorphin: Complete amino acid sequence of the biologically active heptadecapeptide. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 7219-7223.
6. 2 (Tyr-W-MIF-1). Peptides 1992, 13, 623-631.
7. (a) Zadina, J. E.; Hackler, L.; Ge, L.-J.; Kastin, A. J. A potent and selective endogenous agonist for the μ-opiate receptor. Nature 1997, 386, 499-502.
8. (b) Hackler, L.; Zadina, J. E.; Ge, L.-J.; Kastin, A. J. Isolation of relatively large amounts of endomorphin-1 and endomorphin-2 form human brain cortex. Peptides 1997, 18, 1635-1639.
9. Melchiorri, P.; Negri, L. The dermorphin peptide family. Gen. Pharmacol. 1996, 27, 1099-1107.
10. Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Salvadori, S. What peptides these deltorphins be. Prog. Neurobiol. 1999, 57, 377-420.
11. Portoghese, P. S. Bivalent ligands and the message-address concept in the design of selective opioid receptor antagonists. Trends Pharmacol. Sci. 1989, 10, 230-235.
12. (a) Salvadori, S.; Balboni, G.; Guerrini, R.; Tomatis, R.; Bianchi, C.; Bryant, S. D.; Copper, P. S.; Lazarus, L. H. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary δ opioid antagonist activity. J. Med. Chem. 1997, 40, 3100-3108.
13. 2[Ψ] produces a potent analgesic effect, no physical dependence, and less tolerance that morphine in rats. J. Med. Chem. 1999, 42, 3520-3526.
14. (c) Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Copper, P. S.; Lazarus, L. H. Further studies on the Dmt-Tic pharmacophore: Hydrophobic substituents at the C-terminus endow δ antagonists to manifest μ agonism or μ antagonism. J. Med. Chem. 1999, 42, 5010-5019.
15. (d) Page, D.; Naismith, A.; Schmidt, R.; Coupal, M.; Labarre, M.; Gosselin, M.; Bellemare, D.; Payza, K.; Brown, W. Novel C-terminus modifications of the Dmt-Tic motif: A new class of dipeptide analogues showing altered pharmacological profiles toward the opioid receptors. J. Med. Chem. 2001, 44, 2387-2390.
16. (e) Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazarus, L. H. Evaluation of the Dmt-Tic pharmacophore: Conversion of a potent δ opioid antagonist into a potent δ opioid agonist and ligands with mixed properties. J. Med. Chem. 2002, 45, 713-720.
17. (f) Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Bryant, S. D.; Jinsmaa, J.; Lazarus, L. H. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R′ analogues: Acquisition of potent δ antagonism. Bioorg. Med. Chem. 2003, 11, 5435-5441.
18. (a) Lazarus, L. H.; Bryant, S. D.; Cooper, P. S.; Guerrini, R.; Balboni, G.; Salvadori, S. Design of δ-opioid peptide antagonists for emerging drug application. Drug Discovery Today 1998, 3, 284-294.
19. (b) Bryant, S. D.; Jinsmaa, Y.; Salvadori, S.; Okada, Y.; Lazarus, L. H. Dmt and opioid peptides: A potent alliance. Biopolymers (Pept. Sci.) 2003, 71, 86-102.
20. (a) Chandrakumar, N. S.; Yonan, P. K.; Stapelfeld, A.; Savage, M.; Rorbacher, E.; Contreras, P. C.; Hammond, D. Preparation and opioid activity of analogues of the analgesic dipeptide 2, 6-dimethyl-l-tyrosyl-N-(3-phenylpropyl)- d-alaninamide. J. Med. Chem. 1992, 35, 223-233.
21. 5]enkephalin. J. Med. Chem. 1992, 35, 684-687.
22. (c) Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto Y. Biological properties of opioid peptides replacing Tyr at position 1 by 2,6-dimethyl-Tyr. Chem. Pharm. Bull. 1999, 47, 1506-1509.
23. (d) Schiller, P. W.; Berezowska, I.; Nguyen, T. M.-D.; Schimidt, R.; Lemieux, C.; Chung, N. N.; Falcone-Hindley, M. L.; Yao, W.; Liu, J.; Iwama, S.; Smith, A. B.; Hirschmann, R. Novel ligands lacking a positive charge for the δ-and μ-opioid receptors. J. Med. Chem. 2000, 43, 551-559.
24. 2 analogues lacking an N-terminal amino group: Potent and selective κ opioid antagonists. J. Med. Chem. 2001, 44, 3048-3053.
25. (f) Sasaki, Y.; Hirabuki, M.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Enkephalin analogues with 2′,6′-dimethylphenylalanine replacing phenylalanine in position 4. Bioorg. Med. Chem. Lett. 2001, 11, 327-329.
26. (g) Harrison, B. A.; Pasternak, G. W.; Verdine, G. L. 2,6-Dimethyltyrosine analogues of a stereodiversified ligand library: Highly potent, selective, nonpeptidic μ opioid receptor agonists. J. Med. Chem. 2003, 46, 677-680.
27. (h) Weltrowska, G.; Lemieux, C.; Chung, N. N.; Schiller, P. W. A chimeric opioid peptide with mixed μ agonist/δ antagonist properties. J. Pept. Res. 2004, 63, 63-68.
28. 1]endomorphin-2 analogues: Enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg. Med. Chem. 2003, 11, 1983-1984.
29. (b) Fujita, Y.; Tsuda, Y.; Li, T.; Motoyama, T.; Takahashi, M.; Shimizu, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Kita, A.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H.; Okada, Y. Development of potent bifunctional endomorphin-2 analogues with mixed μ/δ-opioid agonist and δ-opioid antagonist properties. J. Med. Chem. 2004, 47, 3591-3599.
30. Okada, Y.; Tsuda, Y.; Fujita, Y.; Yokoi, T.; Sasaki, Y.; Ambo, A.; Konishi, R.; Nagata, M.; Salvadori, S.; Jinsmaa, Y.; Bryant, S. D.; Lazarus, L. H. Unique high-affinity synthetic μ-opioid receptor agonists with central-and systemic-mediated analgesia. J. Med. Chem. 2003, 46, 3201-3209.
31. n]-2(1H)-pyrazinone with central-mediated analgesia. J. Med. Chem. 2004, 47, 2599-2610.
32. Bradbury, A. F.; Smyth, D. G.; Snell, C. R.; Deakin, J. E. W.; Wendlandt, S. Comparison of the analgesic properties of lipotropin C-fragment and stabilized enkephalins in the rat. Biochem. Biophy. Res. Commun. 1977, 74, 748-754.
33. Schiller, P. W.; Yam, C. H.; Lis, M. Evidence for topographical analogy between methionine-enkephalin and morphine derivatives. Biochemistry 1977, 16, 1831-1838.
34. 1 with ring substitution at position 3′. J. Pept. Sci. 2000, 6, 280-289.
35. 5] enkephalin with δ opioid receptor selectivity. J. Med. Chem. 1992, 35, 2384-2391.
36. Coy, D. H.; Kastin, A. J. Tyrosine-modified analogues of methionine-enkephalin and their effects on the mouse vas deferens. Peptides 1980, 1, 175-177.
37. Darlak, K.; Grzonka, Z.; Janicki, P.; Czlonkowski, A.; Gumulka, W. Structure-activity studies of dermorphin. Synthesis and some pharmacological data of dermorphin and its 1-substituted analogues. J. Med. Chem. 1983, 26, 1445-1457.
38. Schiller, P. W.; Nguyen, T. M.-D.; Berezowska, I.; Dupuis, S.; Weltrowska, G.; Chang, N. N.; Lemieux, C. Synthesis and in vitro opioid activity profiles of DALDA analogues. Eur. J. Med. Chem. 2000, 35, 895-901.
39. Sasaki, Y.; Sasaki, A.; Niizuma, H.; Goto, H.; Ambo, A. Endomorphin 2 analogues containing Dmp residue as an aromatic amino acid surrogate with high μ-opioid receptor affinity and selectivity. Bioorg. Med. Chem. 2003, 11, 675-678.
40. Ambo, A.; Niizuma, H.; Sasaki, A.; Kohara, H.; Sasaki, Y. Dermorphin tetrapeptide analogues with 2′,6′-dimethylphenylalanine (Dmp) substituted for aromatic amino acids have high μ opioid receptor binding and biological activities. Bioorg. Med. Chem. Lett. 2003, 13, 1269-1272.
41. Dygos, J. H.; Yonan, E. E.; Scaros, M. G.; Goodmonson, O. J.; Getman, D. P.; Periana, R. A.; Beck, G. R. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 1992, 741-743.
42. (a) Soloshonok, V. A.; Tang, X.; Hruby, V. J. Large-scale asymmetric synthesis of novel sterically constrained 2′,6′-dimethyl- and α-2′,6′-trimethyltyrosine and -phenylalanine derivatives via alkylation of chiral equivalents of nucleophilic glycine and alanine. Tetrahedron 2001, 57, 6375-6328.
43. (b) Tang, X.; Soloshonok, V. A.; Hruby, V. J. Convenient, asymmetric synthesis of enantiomerically pure 2′,6′-dimethyltyrosine (DMT) via alkylation of chiral equivalents of nucleophilic glycine. Tetrahedron: Asymmetry 2000, 11, 2917-2925.
44. Balaban, A. T.; Nenitzescu, C. D. Pyrylium salts obtained by diacylation of olefins. Part II. The two pyrylium salts formed in diacetylation of 2-methylbut-2-ene. J. Chem. Soc. 1961, 3553-3561.
45. Tessier, D. M.; Clark, J. M. Hapten design in the development of competitive enzyme-linked immunosorbent assays for genotoxic metabolites of alachlor. J. Agric. Food Chem. 1999, 47, 3925-3933.
46. Seidel, F.; Schulze, M.; Baltz, H. Autoxidation of 1,3,5- triisopropylbenzene, a new synthesis of phloroglucinol. J. Prakt. Chem. 1956, 3, 278-298.
47. Heck, R. F. Palladium-catalyzed vinylation of organic halides. Org. React. 1982, 25, 345-390.
48. Bryant, S. D.; Salvadori, S.; Okada, Y.; Takahshi, M.; Sasaki, Y.; Lazarus, L. H. Computational chemistry and opioidmimetics: Receptor ligand interaction of three classes of biologically potent peptides. In Peptides 2000, Martinez, J., Fehrentz, J.-A., Eds.; EDK: Paris, 2000; pp 407-408.
49. Pelton, J. T.; Kazmierski, W.; Gulya, K.; Yamamura, H. I.; Hruby, V. J. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for μ opioid receptors. J. Med. Chem. 1986, 29, 2370-2375.
50. (a) Lazarus, L. H.; Salvadori, S.; Santagaga, V.; Tomatis, R.; Wilson, W. E. Function of negative charge in the "address domain" of deltorphins. J. Med. Chem. 1991, 34, 1350-1355.
51. (b) Lazarus, L. H.; Salvadori, S.; Attila, M.; Grieco, P.; Bundy, D. M.; Wilson, W. E.; Tomatis, R. Interaction of deltorphin with opioid receptors: Molecular determinants for affinity and selectivity. Peptides 1993, 14, 21-28.
52. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.